Brief: Spero Therapeutics Q3 EPS USD -0.32
14/11/2024 21:05
Nov 14 (Reuters) - Spero Therapeutics Q3 operating expenses USD 32.062 million. * Q3 income from operation USD -18.593 million * Q3 net income USD -17.437 million
Recent news on Spero Therapeutics
See all newsBrief: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Spero Therapeutics - May Offer Up To $300 Million In Securities - SEC Filing
Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)